Avidity Biosciences

88 articles with Avidity Biosciences

• Avidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference

  3/13/2023

  Avidity Biosciences, Inc. today announced that the company will be presenting two oral presentations and multiple poster presentations at the 2023 MDA Clinical & Scientific Conference in Dallas, Texas, being held March 19-22, 2023.

• Avidity Biosciences to Participate in Upcoming March 2023 Investor Conference

  3/1/2023

  Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating at the following conference.

• Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights

  2/28/2023

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2022 and highlighted recent corporate progress.

• Avidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader

  2/23/2023

  Avidity Biosciences, Inc. today announced that Arthur A. Levin , Ph.D.  has been appointed to the board.

• Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 22, 2023

  2/22/2023

  Avidity Biosciences, Inc. announced that on February 20, 2023, the Compensation Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 27,400 shares of its common stock and 13,700 restricted stock units to three new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.

• Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

  2/14/2023

  Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

• Avidity Biosciences to Participate in Upcoming Investor Conference - February 07, 2023

  2/7/2023

  Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating at the following conference.

• Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 20, 2023

  1/20/2023

  Avidity Biosciences, Inc. announced that on January 20, 2023, the Compensation Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 12,350 shares of its common stock and 6,175 restricted stock units to three new non-executive employees under the Avidity Biosciences, Inc.

• Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

  1/18/2023

  Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

• Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock - December 16, 2022

  12/16/2022

  Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $17.25 per share.

• Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock

  12/15/2022

  Avidity Biosciences, Inc. today announced that it intends to offer and sell, subject to market and other conditions, $150 million of shares of its common stock.

• 

  Avidity Biosciences Stock Soars On New RNA Data

  12/14/2022

  Shares of Avidity Biosciences are soaring following reported early signs of clinical activity and improvement in patients with myotonic dystrophy type 1 (DM1) treated with its RNA-based therapeutic.

• Avidity Announces Positive AOC 1001 Phase 1/2 MARINA™ Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics

  12/14/2022

  Avidity Biosciences, Inc. (Nasdaq: RNA) today announced positive AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA™ trial demonstrating the first-ever successful targeted delivery of RNA into muscle, a revolutionary advancement for the field of RNA therapeutics.

• Avidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights

  11/8/2022

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress.       

• Avidity Biosciences to Participate in Upcoming November 2022 Investor Conferences

  11/1/2022

  Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following upcoming conferences:

• Avidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping

  10/11/2022

  Avidity Biosciences, Inc. (Nasdaq: RNA) today announced the Phase 1/2 EXPLORE44™ clinical trial of AOC 1044 in healthy volunteers and participants with Duchenne muscular dystrophy (DMD), a rare, genetic condition that is characterized by progressive muscle damage and weakness.

• Avidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annual Congress of World Muscle Society

  10/6/2022

  Avidity Biosciences, Inc. (Nasdaq: RNA) today announced the company will be presenting five poster presentations including the MARINA™ study design for myotonic dystrophy type 1 and preclinical and real-world data from the facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD) programs.

• Avidity Biosciences Announces the Phase 1/2 FORTITUDE™ Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy

  9/29/2022

  Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the Phase 1/2 FORTITUDE™ clinical trial of AOC 1020 in adults with facioscapulohumeral muscular dystrophy (FSHD).

• 

  FDA Hits Avidity's AOC for Myotonic Dystrophy Type 1 with Partial Hold

  9/27/2022

  ​​​​​​​The FDA ordered Avidity Biosciences to halt clinical trial enrollment after a patient suffered a "serious adverse event" testing the company's candidate drug for myotonic dystrophy type 1. 

• Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programs

  9/7/2022

  Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, honors National Muscular Dystrophy Awareness Month, an annual observance that raises awareness for families across the nation who are living with neuromuscular diseases.